Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812447 | 1.00 | ODC1 (0.53) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL4812444 | 1.00 | ODC1 (0.53) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7203566 | 0.94 | ODC1 (0.47) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7203565 | 0.94 | ODC1 (0.47) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7201398 | 0.83 | ODC1 (0.50) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7204349 | 0.83 | ODC1 (0.50) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7204351 | 0.83 | ODC1 (0.50) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL7201395 | 0.83 | ODC1 (0.50) | ODC1LMNABLMKDM4EMAPT | |
| SCHEMBL188441 | 0.81 | FDPS (0.41) | ODC1THRBKMT2ACYP1A2FDPS | |
| SCHEMBL5704613 | 0.81 | FDPS (0.41) | ODC1THRBKMT2ACYP1A2FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148627-A1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | LONZA LTD (CH) | 2020-05-14 | — | — | US | disclosed |
| US-7345196-B1 | Convenient process of manufacture for difluoromethylornithine and related compounds | SABINSA CORPORATION (US) | 2008-03-18 | — | — | US | disclosed |
| US-6998502-B1 | Convenient process of manufacture for difluoromethylornithine and related compounds | SABINSA CORPORATION (US) | 2006-02-14 | — | — | US | disclosed |
| CN-1447686-A | D-enantiomers of DFMO and methods of use thereof | ILEX ONCOLOGY INC (US) | 2003-10-08 | — | — | CN | disclosed |
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
| US-4560795-A | α-Halomethyl derivatives of α-amino acids | Merrell Dow France et Cie. (FR) | 1985-12-24 | — | — | US | disclosed |
| US-4496588-A | HALOMETHYL DERIVATIVES OF A-AMINO ACID | MERRELL TORAUDE ET COMPAGNIE (FR) | 1985-01-29 | — | — | US | disclosed |
| US-4438270-A | DECARBOXYLASE INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4399151-A | USING A-SUBSTITUTERD AMINES OR A-SUBSTITUTED AMINO ACIDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4336054-A | AMINO ACIDS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1982-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | ODC1 34/4885LMNA 3450/4885BLM 1907/4885 |
| US-20200148627-A1 | METHOD FOR PREPARATION OF DIFLUOROMETHYLORNITHINE | SMYD3, MCM3, HLCS | ODC1 4/4885LMNA 638/4885BLM 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.